Evidence map›Paper›PMID 38139866›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Beta Blockers Improve Prognosis When Used Early in Patients with Cardiogenic Shock: An Analysis of the FRENSHOCK Multicenter Prospective Registry.

Laura Sofia Cardelli, Miloud Cherbi, Fabien Huet, Guillaume Schurtz, Eric Bonnefoy-Cudraz, Edouard Gerbaud, Laurent Bonello, Guillaume Leurent, Etienne Puymirat, Gianni Casella and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

Laura Sofia CardelliCardiology Department, Ospedale Versilia, 55049 Camaiore, Italy.ORCID 0000-0003-4454-1864
Miloud CherbiIntensive Cardiac Care Unit, Rangueil University Hospital, 31059 Toulouse, France.
Fabien HuetDepartment of Cardiology, Centre Hospitalier Bretagne Atlantique, 56000 Vannes, France.ORCID 0000-0002-7670-0455
Guillaume SchurtzDepartment of Cardiology, Urgences et Soins Intensifs de Cardiologie, CHU Lille, University of Lille, Inserm U1167, 59000 Lille, France.
Eric Bonnefoy-CudrazIntensive Cardiac Care Unit, Lyon Brom University Hospital, 69677 Lyon, France.
Edouard GerbaudIntensive Cardiac Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut Lévêque, 5 Avenue de Magellan, 33604 Pessac, France.ORCID 0000-0003-4669-3562
Laurent BonelloIntensive Care Unit, Department of Cardiology, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Aix-Marseille University, 13015 Marseille, France.
Guillaume LeurentDepartment of Cardiology, CHU Rennes, Inserm, LTSI-UMR 1099, Univ Rennes 1, 35000 Rennes, France.ORCID 0000-0001-9940-3843
Etienne PuymiratAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, 75015 Paris, France.
Gianni CasellaCardiology Department, Ospedale Maggiore, 40131 Bologna, Italy.
Clément DelmasIntensive Cardiac Care Unit, Rangueil University Hospital, 31059 Toulouse, France.ORCID 0000-0001-9180-9128
François RoubillePhyMedExp, INSERM, CNRS, Cardiology Department, INI-CRT, Université de Montpellier, 34295 Montpellier, France.ORCID 0000-0002-5288-9687
Hôpital Rangueil · FRInserm · FRAix-Marseille Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre hospitalier Bretagne Atlantique · FRCentre National de la Recherche Scientifique · FRFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHôpital Cardiologique du Haut-Lévêque · FROspedale Versilia · IT

Funding

DAICHI NAMAQUET NASociété Française de Cardiologie NA
6 · The paper itself

Abstract

backgroundBeta blockers (BBs) are a cornerstone for patients with heart failure (HF) and ventricular dysfunction. However, their use in patients recovering from a cardiogenic shock (CS) remains a bone of contention, especially regarding whether and when to reintroduce this class of drugs.

methodsFRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers. Our aim was to compare outcomes (1-month and 1-year all-cause mortality) between CS patients taking and those not taking BBs in three scenarios: (1) at 24 h after CS; (2) patients who did or did not discontinue BBs within 24 h; and (3) patients who did or did not undergo the early introduction of BBs.

resultsAmong the 693 CS included, at 24 h after the CS event, 95 patients (13.7%) were taking BB, while 598 (86.3%) were not. Between the groups, there were no differences in terms of major comorbidities or initial CS triggers. Patients receiving BBs at 24 h presented a trend toward reduced all-cause mortality both at 1 month (aHR = 0.61, 95% CI 0.34 to 1.1,

conclusionsBBs are drugs of first choice in patients with HF and should also be considered early in patients with CS. In contrast, the discontinuation of BB therapy resulted in increased 1-month all-cause mortality and a trend toward increased 1-year all-cause mortality.

Indexed as

acute heart failurebetablockercardiogenic shockone-month mortalityone-year mortality

Identifiers

PMID38139866
PMCPMC10747751
OpenAlexW4389919487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.